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Ortho-Phthalaldehyde (OPA) has been approved for high-level sterilization of heat-sensitive medical instruments and is
increasingly being used as a replacement in the healthcare industry for glutaraldehyde, a known sensitizer. Numerous case reports
have been published indicating workers and patients experiencing respiratory problems, anaphylaxis, skin reactivity, and systemic
antibody production. Our laboratory previously demonstrated that OPA is a dermal sensitizer in mice. The goal of the present
studywastodetermineifOPAisarespiratorysensitizerfollowinginhalationexposure.MicewereexposedtoOPAvaporandairway
and lymph nodes were examined for cytokine gene expression and alterations in lymphocyte populations. Inhalation of OPA for
3 days resulted in a concentration-dependent increase in lymphocyte proliferation, mainly B lymphocytes, in the draining lymph
nodes. A secondary challenge of mice with OPA resulted in a dramatic increase in the population of B lymphocytes expressing IgE.
Expression of Th2 (IL-4, IL-5, and IL-13) and anti/proinﬂammatory (IL-10, TNFα,a n dI L - 1 β) cytokine genes was upregulated in
the lymph nodes and the nasal mucosa. Mice exposed to the higher concentrations of OPA-produced OPA-speciﬁc IgG1 antibodies
indicating systemic sensitization. These ﬁndings provide evidence that OPA has the potential to cause respiratory sensitization in
mice.
1.Introduction
Ortho-Phthalaldehyde(OPA)isanaromaticdialdehyde,used
as a high-level antimicrobial disinfectant for medical equip-
ment which is sensitive to normal heat or steam sterilization
processes, including endoscope, cystoscopes, and certain
dental instruments. For 40 years, glutaraldehyde, another
dialdehyde, has been the primary choice for disinfecting
heat-sensitive medical devices; however, it has been reported
to be a chemical sensitizer. Glutaraldehyde is known to have
high aﬃnity for biological amines, and its use as a tissue
ﬁxative capitalizes on this property. As such, glutaraldehyde
and dialdehydes as a chemical class can bind to native
proteins, thus, altering their presentation to the immune
system. Haptenization of native proteins can lead to an aber-
rant immune response and the development of allergy.
SeveralhumanstudieshavedemonstratedthepresenceofIgE
antibodiesspeciﬁcforglutaraldehydeadductsintheserumof
exposed workers with respiratory disease [1, 2]. Importantly,
workplace exposure to glutaraldehyde is known to induce
occupational asthma [2–4] and allergic contact dermatitis
[5] suggesting the need for safer alternatives. OPA has shown
superior antimycobactericidal activity as compared to glu-
taraldehyde [6], allowing for its use at lower concentrations.
In addition, low volatility and no need for activation have
increased the use of OPA as a more practical alternative to
glutaraldehyde.
Itisestimatedthat3253workerswerepotentiallyexposed
to OPA compared to 376,330 for glutaraldehyde from 1981–
1983 [7]. If OPA was fully adopted as an alternative for
glutaraldehyde, it is a reasonable assumption that more than
300,000 US workers could now be exposed. The estimated
use of OPA in 2002 was between 10,000 and 500,000 pounds
[8]. OPA is commonly considered as a “safe” alternative to2 Journal of Allergy
glutaraldehyde despite a paucity of information regarding
the toxicity of this chemical and the potential health eﬀects
associated with exposure. Very few toxicology studies are
available in the published literature to establish the safety
of OPA. The few toxicity studies that have been performed
suggest that OPA may be a chemical irritant and sensitizer
and may act as an adjuvant for other allergens [9–12].
Currently there are no regulations regarding proper use
and safe exposure levels of OPA in spite of the potential
of exposure for a large number of healthcare workers and
their patients. Concentrations of OPA ranging from 1.0 to
13.5ppb have been detected in air samples collected from an
endoscope cleaning unit of a hospital that used OPA as its
primary disinfectant [13–15].
Several case reports have been presented in the litera-
ture questioning the safe substitution of OPA as a high-
level sterilant in the healthcare industry. Fujita et al. [15]
investigated a case involving a female nurse who exhibited
slight dyspnea and dry cough that began a few months after
switchingtoOPAforhigh-levelsterilizationintheendoscopy
unit. The patient was subsequently diagnosed with bronchial
asthma and experienced episodic attacks when working
in the endoscopy unit. Another report identiﬁed four
patients who experienced nine episodes of anaphylaxis with
associated respiratory symptoms after a urology practice
switched from using glutaraldehyde to OPA for cystoscope
disinfection [16]. In a separate report, anaphylactic reactions
with respiratory involvement occurred in two bladder cancer
patients following repeated cystoscopic examination of their
tumors [17] and a woman receiving repeated checkups by
laryngoscopy [18, 19]. Two potential cases of occupational
asthma in healthcare workers disinfecting endoscopes and
similar deviceswithOPAhavealsobeen reported [20].These
case reports demonstrate that occupational and medical
exposure to OPA can induce systemic anaphylaxis as well as
pose a risk of respiratory sensitization.
Toxicity data derived from animal studies will be impor-
tant for regulating and setting occupational exposure limits
for OPA. Our laboratory recently demonstrated that mice
dermally exposed to OPA tested positive in the local lymph
node assay (LLNA) with associated increases in total and
OPA-speciﬁc IgE levels, suggesting an IgE-mediated allergic
mechanism [9]. The EC3 value for OPA was 0.051%, ten-
fold lower than the working concentration for disinfection,
establishing this chemical as a strong dermal sensitizer. The
goal of the present studies was to determine the respiratory
sensitization potential of inhalation exposure to OPA vapor.
2. Methods
2.1. OPA Exposure System. In order to study the potential
for the inhalation of OPA to cause respiratory sensitization,
a nose-only exposure system was developed to minimize
skin contact. The OPA exposure system consists of two
major components, the vapor generator and the nose-only
inhalation tower. Brieﬂy, OPA (0–1000ppb) was dissolved in
ddH2O as a vehicle for delivery to the generator. The OPA
generator consisted of a stainless steel septum T that was
heated with a variable resistance heat rope to an internal
air temperature of 105◦C, a temperature that would ensure
complete vaporization of the water vehicle. Air ﬂow through
the generator and exposure system was set at 10LPM, and
temperature of the system was controlled at 74 ± 2◦C. This
ﬂowrateequatedto1LPM/activeexposureportonthenose-
only tower and is suﬃc i e n tt oe n s u r ea d e q u a t er e m o v a lo f
exhalation gases to prevent dilution of the OPA atmosphere
and rebreathing of respiratory gases, namely, CO2 [21]. A
KDS100 syringe pump (KD Scientiﬁc Inc., Holliston, MA)
was used to inject the OPA/vehicle (water) into the generator
at a ﬂow rate of 117μL/min conditioning the system air
to 50 ± 3% relative humidity. Temperature and humidity
were monitored using an HMP243 humidity/temperature
transmitter(VaisalaInc.,Woburn,MA)placedinanose-only
restrainer to position the sensor in the breathing zone. The
concentration of the OPA injection solution was adjusted
to provide the desired OPA vapor concentration given the
ﬁxed injection rate of 117μL/min. The OPA/air mixture
then entered a mixing chamber prior to the nose-only
inhalation tower. The exposure atmosphere was pumped
into the directed-ﬂow nose-only exposure tower (InTox
Products, Moriarty, MN). A vacuum was applied to the
exhaust plenum to maintain a constant negative pressure of
−0.1 inches water across the exposure tower controlled by
a real-time electronic pressure controller (Alicat Scientiﬁc,
Tucson, AZ) that monitored and dynamically adjusted the
pressure within the exhaust plenum. This minimized leaks
to atmosphere as well as ensured suﬃcient removal of
respiratorygasesfromthebreathingzone.Micewereexposed
to OPA using nose-only restrainers. The calculated OPA
vapor concentration was conﬁrmed empirically using a
laboratory assay based upon the ﬂuorescenceof OPA-protein
conjugates. Air samples from the inhalation tower were
sampled from the breathing zone of a free exposure port
using a midget impinger. The sample was used to detect a
ﬁxed concentration of L-alanine as the amine acceptor, and
the OPA concentration was determined relative to an OPA
standard curve monitored at 442nm.
2.2. Experimental Animals. Female speciﬁc-pathogen-free
inbred C57BL/6 mice were purchased from Jackson Labora-
tories (Bar Harbor, ME) at 6 to 7 weeks of age. Upon arrival,
the mice were quarantined for 2 weeks and acclimated to a
12-hour light/dark cycle. Animals were housed in ventilated
microisolatorcagesinenvironmentallycontrolledconditions
at NIOSH animal facilities in compliance with AAALAC-
approved guidelines and an approved IACUC protocol.
The animal rooms were monitored for speciﬁc pathogens
through disease surveillance and a sentinel animal program.
Food and water were provided ad libitum.M i c ew e r er a n -
domizedacrosstwoexposureparadigms(Figure 1)eachwith
a control (ﬁltered and conditioned air) and four concen-
trations of OPA (125–1000ppb). The sensitization exposure
paradigm involved 4-hour inhalation exposures (4 hours/
exposure) on day 1–3 followed by euthanasia 48 hours
after ﬁnal exposure. The sensitization/challenge exposure
paradigm consisted of inhalation exposure on days 1–3 and
again on days 16–18 followed by sacriﬁce 48 hours later.Journal of Allergy 3
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Figure 1: OPA inhalation and sacriﬁce schedule.
The exposure environment was maintained at 74 ± 2◦Ca n d
50 ±3% relative humidity.
2.3. Tissue Collection. Mice were sacriﬁced via pentobarbital
overdose (200mg/kg, i.p.) 48 hours following the ﬁnal
exposure. Blood was collected from the abdominal aorta and
serum was isolated and frozen at −80◦C until assessment
of antibody production. For gene expression analysis, the
head was removed and the nasal cavity was ﬂushed with
RNAlater (Qiagen, Valencia, CA), the skin and fur, top of the
skull, brain and lower jaw were removed and the remaining
t i s s u ew a ss t o r e di n1 0v o l u m e so fR N A l a t e ra t4
oC until
dissection and tissue removal (3 days). The left mandibular
lymphnodesandthelungswereremoved,lungswereinﬂated
with RNAlater, and then the tissues were stored in 10
volumesofRNAlaterat −20◦CuntilRNAextractionforPCR
analysis. The nasal cavity was opened by removing the nasal
bones and ﬂattening the skull along the anterior-posterior
axis. Using blunt dissection in RNAlater, the nasal mucosa
lining the maxilloturbinates and lateral wall were removed
as a single sample and stored at −20◦C in RNAlater until
processed for microarray and PCR gene expression analysis.
Therightmandibularlymphnodeswereremovedandplaced
in3mLPBSat4◦Candquicklyprocessedforﬂowcytometric
phenotyping as described below.
2.4. OPA-Speciﬁc Antibody Detection. OPA-speciﬁc immun-
oglobulin G1 (IgG1) and IgE serum antibodies were detected
using an ELISA procedure as previously described [9].
Brieﬂy, Immulon-4 microtiter plates (Nunc, Thermo Sci-
entiﬁc) were coated overnight at 4◦C with mouse serum
albumin(MSA;10μg/mLincarbonatebuﬀer,pH9.5).Plates
were washed 3 times with 0.05M borate buﬀer followed by
the addition of 0.5% OPA in distilled deionized water for 1
hour at room temperature. Plates were washed 3 times with
PBS/0.05% Tween-20 wash buﬀer, and nonspeciﬁc binding
sites were blocked with 1% BSA in PBS/0.05% Tween-20 for
30 minutes. A two-fold dilution series (1/10 to 1/5120) of
serum was added to wells coated with MSA-only and wells
withOPA-conjugatedMSAandincubatedfor2hoursat4◦C.
Plates were washed 3 times with PBS/0.05% Tween-20, and
then biotin-conjugated antibodies speciﬁc for mouse IgG1 or
IgE (BD Biosciences, San Jose, CA) were added for 1 hour
at 4◦C. Finally, plates were washed 4 times, and avidin-HRP
w a sa d d e df o r3 0m i n u t e sa tr o o mt e m p e r a t u r ef o l l o w e db y
4 washes. TMB-Turbo substrate (Thermo Fisher Scientiﬁc,
Pierce, Rockford, IL) was added for 30 minutes followed
by the addition of 2M H2SO4 stop solution. Absorbance
was read on a SpectraMax plate reader (Molecular Devices,
Sunnyvale, CA) at 650nm during color development and at
450nm following addition of stop solution.
2.5. Assessment of Nasal Mucosa Gene Expression. Total cellu-
lar RNA was extracted from the nasal mucosa using the Qia-
genRNeasykit(Qiagen,Valencia,CA)accordingtotheman-
ufacturer’s instructions following homogenization in RLT
buﬀerusingaTissueLyserII(Qiagen,Valencia,CA)beadmill
system. One μg of RNA was reverse-transcribed using ran-
dom hexamers and 60U of Superscript II (Life Technologies,
Grand Island, NY). Real-time PCR primer/probe sets for
murine IL-1β, IL-4, IL-5, IL-13, IFNγ,T N F α, and 18s were
purchased from Applied Biosystems (Foster City, CA). Real-
time PCR was performed using Taqman Universal Master
mix with Amperase in an Applied Biosystems 7900HT
(Applied Biosystems, Foster City, CA) for 1 cycle at 50◦C
for 2 minutes, and 95◦C for 10 minutes, followed by 60
cycles at 95◦C for 15 seconds and 60◦Cf o r1m i n u t e .R e l a t i v e
diﬀerences in mRNA expression between control and treat-
ment groups were determined by the relative quantiﬁcation
method developed by Pfaﬄ [22]. This method uses gene
speciﬁc PCR eﬃciencies to more accurately generate relative
changes based on threshold cycle. Target gene expression was
normalized to the housekeeping gene 18s/rRNA.
2.6. Flow Cytometric Phenotyping of Draining Lymph Nodes.
All antibodies and isotype controls for phenotyping T
and B lymphocytes were purchased from BD Pharmingen
(San Jose, CA). The right mandibular lymph nodes that
drain the nasal mucosa were collected in 3mL PBS and
dissociated using the frosted ends of two microscope slides.
Cell counts were performed using a Coulter Counter (Z2
model, Beckman Coulter, Brea, CA), and 1 × 106 cells per
sample were added to the wells of a 96-well plate. Cells
were washed using staining buﬀer (0.2% bovine serum
albumin/0.1% sodium azide in DPBS; BD Pharmingen,
San Jose, CA) and then incubated for 10 minutes with Fc4 Journal of Allergy
block (clone 2.4G2). The cells were then incubated with
anti-CD3 (APC, clone 145-2C11)/anti-CD4 (FITC, clone
RM4-5)/anti-CD8 (PE, clone 53-6.7) or anti-CD45RA/B220
(PE, clone RA3-6B2)/anti-IgE antibodies (FITC, clone R-35-
72) or the appropriate isotype controls diluted in staining
buﬀer for 30 minutes. Cells were washed, incubated with
propidium iodide (PI) for 5 minutes to stain dead cells.
After a ﬁnal wash, cells were resuspended in staining buﬀer
and analyzed with a FACSCaliber ﬂow cytometer (Becton
Dickinson, San Jose, CA) using a PI viability gate. Data for
a total of 10,000 cells were collected based on the forward-
side scatter lymphocyte gate.
2.7.StatisticalAnalysis. TheOPAinhalationexposuresystem
is capable of exposing mice to a single concentration with an
equivalent inhalation tower used for the concurrent control
group. Therefore, all concentrations for each exposure
paradigm (Figure 1) required its own concurrent control,
andalldataanalysiswasperformedrelativetotheconcurrent
control. Treatment eﬀects were determined using a Student’s
t-test comparing a single OPA concentration to the concur-
rent control. Diﬀerences were considered signiﬁcant at P<
.05. For clarity of presentation, data have been normalized
to the concurrent control group and shown as fold change,
unless otherwise stated.
3. Results
3.1. OPA Inhalation Did Not Induce Overt Signs of Systemic
Toxicity and Respiratory Distress. Inhalation exposure to
OPA did not cause observable clinical signs of systemic
toxicity or respiratory distress throughout the exposure dose
response. All mice actively groomed following each exposure
period and were observed to eat and drink shortly after
exposure. However, mice treated with 1000ppb OPA for
3 days followed by sacriﬁce on the 5th day (sensitization
exposure; Figure 1) had lost approximately 10% of their
initial body weight versus 1.9% in the controls. Over the
rest period, mice regained weight at a similar rate as the
control group. Subsequent inhalation challenge with the
same OPA concentration (sensitization/challenge exposure;
Figure 1)resultedinasmallerbodyweightloss(5%lossfrom
initial body weight). Similar body weight loss was observed
in mice exposed to 500ppb OPA but concentrations below
500ppb showed similar body weight changes as observed in
the control mice (data not shown). No mice died from OPA
inhalation prior to the scheduled study termination.
3.2. Inhalation Exposure to OPA Vapor Induced the Produc-
tion of OPA-Speciﬁc Antibodies. Serum was collected and
evaluated to determine if mice exposed to OPA developed
systemic sensitization resulting in the production of anti-
bodies speciﬁc for OPA-conjugated protein. No OPA-speciﬁc
antibodies were observed in any of the control mice or mice
exposedtoOPAusingthesensitizationexposure.Incontrast,
inhalationchallengeofmiceto ≥500ppbOPAvaporresulted
in OPA-speciﬁc IgG1 production. The OD450 values were
1.76 ± 0.02 and 1.35 ± 0.35 for a 1/20 dilution of serum
from mice treated with 500 or 1000ppb OPA, respectively,
versusabackgroundOD450 inthecontrolseraof0.086±0.02.
Serum from mice treated with 500 and 1000 ppb OPA also
showed mild antibody speciﬁcity for native MSA as observed
in our previous studies following dermal exposure to OPA
[9]. OPA-speciﬁc IgE was not detected in the serum of any
mice (data not shown).
3.3. OPA Inhalation Induces Cytokine Gene Expression in
the Airways and Draining Lymph Nodes. Gene expression
analysis of key cytokine genes can provide insight into
the immunotoxicity of inhaled chemicals especially when
examined in the target mucosal tissue lining the airways and
the associated draining lymph nodes. Pro/anti-inﬂammatory
cytokines (IL-10, TNFα,I L - 1 β) are important in the initial
stages of an immune response to a chemical sensitizer and
can shape the developing immune response towards Th1
immunity (IFNγ), Th2 immunity (IL-4, IIL-5, IL-13), or a
combination. Sensitization and allergy are supported mainly
by Th2 cytokine responses although Th1 cytokines have
been shown to be important for chemical sensitizers [23].
Lymph nodes in the cervical region drain the skin of the
head and the nasal mucosa. Since OPA is a highly reactive
chemical, the mandibular lymph nodes draining the nasal
mucosa, a target site, were examined for gene expression
changes. The inhalation of OPA during sensitization resulted
in concentration-dependent upregulation of IL-4 and IL-5
expression (signiﬁcant increases ≥500ppb OPA; Table S1)
in the mandibular lymph nodes (Figure 2). The expression
of TNFα,I L - 1 β, and IL-10 were also increased in the lymph
nodes of mice treated with 1000ppb OPA. Subsequent OPA
challenge for an additional 3 days resulted in increased IL-4
gene expression throughout the concentration range tested
(Figure 2; Table S1). The expressions of IL-10 and IL-1β were
also increased in the lymph nodes following challenge with
OPA although to a lesser extent than following sensitization
alone (Figure 2;T a b l eS 1 ) .
The inhalation of OPA also increased cytokine gene
expression in the mucosal tissue lining the upper airways
(Figure 3; Table S1). Increased IL-4 expression in mice
exposed to 1000ppb OPA and a concentration-dependent
stimulation of IL-1β in the nasal mucosa occurred in mice
exposed to OPA during sensitization only suggesting acute
inﬂammation. Challenging mice after an 11-day rest period
to the same concentration of OPA vapor for an additional
3 days caused marked concentration-dependent increases in
all of the cytokine genes interrogated. IL-4, IL-5, and IL-1β
were upregulated at all concentrations of OPA while IL-13,
IFNγ,T N F α, and IL-10 were increased at ≥500ppb. Mice
that inhaled the higher concentrations of OPA also showed
increased expression of IL-4, IL-5, IL-13, and IL-1β in the
lung tissues although not statistically signiﬁcant (Figure 4;
Table S1).
3.4. Respiratory Exposure to OPA Induces Lymphocyte Prolif-
eration and an Allergic Phenotype in the Mandibular Lymph
Nodes. A hallmark characteristic of respiratory allergy is
proliferation of lymphocytes, namely, B lymphocytes in the
lymph nodes draining the target tissue. OPA inhalationJournal of Allergy 5
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Figure 2: Inhalation of OPA vapor induces the expression of Th2 and pro/anti-inﬂammatory cytokines in the draining lymph nodes of mice.
Mice were exposed to OPA (125, 250, 500, 1000ppb) or ﬁltered air according to the schedule shown in Figure 1. Two days following
the ﬁnal exposure, the mandibular lymph nodes from the left side of the neck were removed and processed for gene expression analysis.
Data are presented as mean (n = 5) and represent fold change relative to the concurrent control group. ∗Indicates that the cytokine was
signiﬁcantly increased at one or more of the OPA concentrations. Refer to Table S1 of the supplementary material available online at doi:
10.1155/2011/751052 for the empirical gene expression data.
resulted in a concentration-dependent increase in total lym-
phocytes in the mandibular lymph nodes with a maximum
increase of approximately 4 fold over the control mice
(Figure 5). Both T lymphocytes and B lymphocytes were
increased in the lymph nodes of OPA-exposed mice, how-
ever, the increase in B lymphocytes was much greater. The
ratio of T:B lymphocytes was reduced in a concentration-
dependent manor in mice treated with OPA reﬂecting
the greater proliferation of B lymphocytes relative to T
lymphocytes(Table 1).TheratioofCD4:CD8Tlymphocytes
in the draining lymph nodes did not change in any of the
treatment groups relative to the controls (data not shown).
3.5. OPA Inhalation Induces Isotype Switching to IgE+ BL y m -
phocytes in the Draining Lymph Nodes. An important char-
acteristic of an allergic response is the isotype switch to6 Journal of Allergy
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Figure 3: Inhalation of OPA vapor induces the expression of Th2, Th1, and pro/anti-inﬂammatory cytokines in the nasal mucosa of mice. Mice
were exposed to OPA (125, 250, 500, 1000ppb) or ﬁltered air according to the schedule shown in Figure 1. Two days following the ﬁnal
exposure, the mucosal tissue lining the maxilloturbinates and lateral wall of the nasal cavity were removed and processed for gene expression
analysis. Data are presented as mean (n = 5) and represent fold change relative to the concurrent control group. ∗Indicates that the cytokine
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IgE producing B lymphocytes. We utilized multicolor ﬂow
cytometry to identify the B lymphocyte population in the
draining lymph nodes and enumerated the IgE+ and IgE−
populations using an anti-IgE antibody. Figure 6 shows that
inhalation exposure to OPA during sensitization only did
not induce isotype switching to IgE+ B lymphocytes at any
concentration tested. In contrast, inhalation challenge 11
days later to the same OPA concentration resulted in a
marked increase in the number of B lymphocytes expressing
IgE indicating isotype switching to IgE (Figure 6). The
percentage of total B-lymphocytes producing IgE in the
mandibular lymph nodes increased from 7.32±1.08% in the
control group to 11.38 ± 0.99, 34.01 ± 5.06, 41.62 ± 8.72,
and 22.67 ± 2.09% in mice exposed to 125, 250, 500, and
1000ppb OPA, respectively. These eﬀects were signiﬁcant at
all concentrations of OPA tested.
4. Discussion
Ortho-Phthalaldehyde has been approved by the FDA for
the high-level disinfection of reusable heat sensitive medical/
dental instruments [24] and is increasingly being substitutedJournal of Allergy 7
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Figure 4: Eﬀect of respiratory exposure to OPA vapor on the expression of Th2, Th1, and pro/anti-inﬂammatory cytokines in the lungs of mice.
Mice were exposed to OPA (125, 250, 500, 1000ppb) or ﬁltered air according to the schedule shown in Figure 1. Two days following the ﬁnal
exposure, the lungs were removed, inﬂated with RNALater, and processed for gene expression analysis. Data are presented as mean (n = 5)
and represent fold change relative to the concurrent control group. ∗Indicates that the cytokine was signiﬁcantly increased at one or more of
the OPA concentrations. Refer to Table S1 for the empirical gene expression data.
for glutaraldehyde in the healthcare industry. Approval was
rendered despite a lack of toxicity data supporting OPA as
a safe alternative. There have been numerous case reports
on skin and respiratory complications in healthcare workers
and patients exposed to OPA suggesting similar health risks
to glutaraldehyde. The goal of the present studies was to
determine if OPA has the potential to act as a respiratory
sensitizer following inhalation exposure. Our previous stud-
ies demonstrated that OPA was a potent dermal sensitizer
following skin exposure [9]. In order to study the potential
for the inhalation of OPA to cause respiratory sensitization,
a nose-only exposure system was developed to minimize
skin contact. Cytokine gene expression and lymphocyte
phenotyping in the respiratory mucosa and draining lymph
nodesprovideevidencethatOPAisarespiratorysensitizer in
mice.
OPA is a highly reactive chemical with an aﬃnity for
biological amines, a property exploited in its use as a biocidal8 Journal of Allergy
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Figure 5: OPA inhalation stimulates B- and T-lymphocyte proliferation in the draining lymph nodes of mice. Mice were exposed to OPA or
ﬁltered air according to the schedule shown in Figure 1. Two days following the ﬁnal exposure, the mandibular lymph nodes from the right
side of the neck were removed and immediately processed into single-cell suspensions. Scatter properties were used to identify lymphocytes
followedbyﬂuorescentantibodieslabelingtoidentifyBlymphocytes,Tlymphocytes(total,CD4+ andCD8+)usingﬂowcytometry.Dataare
presentedasfoldchangerelativetotheconcurrentcontrol.Statisticalanalysiswasperformedontheabsolutecellcountsforeachlymphocyte
population. Hatched bars represent mice that were exposed for 3 days followed by sacriﬁce on day 5 (sensitization exposure, Figure 1). Solid
bars represent mice that were exposed on d1–d3, d16–d18 and sacriﬁced on d20 (sensitization/challenge exposure, Figure 1). Mean ± SEM
(n = 5). ∗Signiﬁcantly diﬀerent from concurrent control group at P<. 05. Absolute cell counts are presented in Table S2.Journal of Allergy 9
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Figure 6: OPA inhalation induces isotype switching in B lymphocytes
to IgE. Mice were exposed to OPA or ﬁltered air according to the
schedule shown in Figure 1. Two days following the ﬁnal exposure,
the mandibular lymph nodes from the right side of the neck were
removed and immediately processed into single-cell suspensions.
Scatter properties were used to identify lymphocytes followed by
ﬂuorescent antibodies labeling to identify B lymphocytes using ﬂow
cytometry. Fluorescent anti-IgE antibodies were used to identify B-
lymphocyteexpressingIgEontheirmembrane.Openbarsandopen
diamonds represent mice that were exposed OPA or ﬁltered air,
respectively, for 3 days followed by sacriﬁce on day 5 (sensitization
exposure, Figure 1). Stippled bars and open triangles represent
mice that were exposed OPA or ﬁltered air, respectively, on d1–d3,
d16–d18 and sacriﬁced on d20 (sensitization/challenge exposure,
Figure 1). Mean ± SEM (n = 5). ∗Signiﬁcantly diﬀerent from
concurrent control group at P<. 05.
Table 1: Inhalation of OPA skews the lymphocyte population heav-
ily towards B lymphocytes in the mandibular lymph nodes.
OPA (ppb)
T-lymphocyte/B-lymphocyte Ratio
(Fold change from concurrent control)
Sensitization Exposure
125 1.19 ± 0.09a
250 −1.41 ± 0.19
500 −3.22 ±0.24∗
1000 −3.20 ±0.29∗
Sensitization/Challenge
Exposure
125 −1.58 ±0.08∗
250 −1.56 ±0.11∗
500 −2.39 ±0.29∗
1000 −4.13 ±0.20∗
∗Signiﬁcantly diﬀerent from concurrent control group at P<. 05.
aMean ± SEM (n = 5).
agent. This property is also exploited for the detection
of biomolecules since upon interaction with amines, OPA
becomes highly ﬂuorescent [25]. By virtue of its ability
to react with proteins, OPA may also act as a hapten
in biological systems and could possibly lead to aber-
rant immune and allergic reactions. These hapten reactions
form the basis for sensitization resulting from exposure to
reactive low molecular weight chemicals in the workplace.
The present work shows that the inhalation of OPA results
in the systemic production of IgG1 antibodies that are
speciﬁcforOPA-MSA,supportiveevidencethatOPA-protein
conjugates formed invivoareimmunogenic.Theproduction
of IgG1 in by B lymphocytes requires support from CD4+ T
lymphocytesproducingIL-4andIL-5whichfacilitateisotype
switching and maturation, respectively [26]. Passive transfer
of chemical-speciﬁc IgG antibody to na¨ ıve mice has been
shown to induce respiratory symptoms following exposure
to toluene diisocyanate [27] and trimellitic anhydride [28]
indicating a potential role for IgG in the pathogenesis of
chemical-induced airway allergy. It is also possible that OPA-
speciﬁc IgG1 may represent a marker of exposure as has been
suggested for diisocyanates [29, 30].
OPA-speciﬁc IgE was not detected following inhalation
exposure; however, aggressive dermal exposure of mice to
OPA resulted in the production of OPA-speciﬁc IgG1,I g G 2a,
and IgE isotypes supporting an allergic immune response
to this chemical [9]. Similar chemical-hapten-speciﬁc anti-
body responses have been observed in rodent models for
other low molecular weight chemicals including toluene
diisocyanate [23, 31] and trimelitic anhydride [32]. OPA-
speciﬁc antibodies have been detected in the serum of
healthcare workers experiencing respiratory and dermal
symptoms resulting from workplace exposure to OPA [18].
The presence of OPA-speciﬁc antibodies in the serum of
sensitized workers may result from dermal and/or airway
exposure. Importantly, basophils from healthcare workers
were shown to have bound OPA-speciﬁc IgE as in vitro
culture with 0.55% OPA solution resulted in histamine
release that was similar to treating the cells with anti-IgE
antibody [18]. This demonstrates a functional importance of
OPA-speciﬁc antibodies.
A hallmark feature of chemical sensitizers is a positive
reaction in the local lymph nodes assay (LLNA). Our
laboratoryshowedthatOPAtestedpositiveintheLLNAwith
an EC3 of 0.051% [9]. This suggests that OPA is a powerful
dermal sensitizer and may cause health risks when in contact
with the skin at concentrations as much as 10 fold below
the eﬀective working concentration (0.55%) for disinfecting
medical devices. Recently, a similar approach to the dermal
LLNA has been presented forthe identiﬁcation of respiratory
sensitizers. The respiratory LLNA utilizes inhalation as the
route of exposure and examines the lymph nodes that drain
the nasal mucosa for lymphocyte proliferation [33]a n d
cytokine production [34]. Although the traditional LLNA
endpoint of H3 incorporation as a metric of lymphocyte
proliferation was not used in the present study, mice that
were exposed to OPA by inhalation showed a concentration-
dependent increase in the absolute and relative lymphocyte
counts in the mandibular lymph nodes. This response was
signiﬁcant at concentrations ≥250ppb OPA following the
3 days of inhalation as well as in mice that were reexposed
for an additional 3 days. B lymphocytes accounted for the
majority of the proliferation suggesting a shift towards a
humoral immune response. Although T-lymphocyte num-
bers also increased in the mandibular lymph nodes, the ratio
of CD4:CD8 T cells remained unchanged (data not shown).10 Journal of Allergy
Isotype switching to IgE is a cardinal feature of a type
I hypersensitivity response. The serum of mice exposed to
OPA via inhalation was negative for IgE antibodies speciﬁc
for OPA-MSA although our previous work showed that
dermal exposure to OPA did induce OPA-speciﬁc IgE [9].
The lack of systemic IgE may be due to the sensitivity of the
ELISA assay or may result from a less aggressive sensitization
response following inhalation exposure relative to dermal.
Phenotyping the B-lymphocyte population in the draining
l y m p hn o d e sc a np r o v i d ec l u e st ot h ei s o t y p es p e c i ﬁ c i t y
of the proliferating population. It has been shown that B
lymphocytes from the lymph nodes of mice exposed to Th2
respiratory sensitizers are positive for IgE on their plasma
membrane [35–38]. The inhalation of OPA vapor during
sensitization did not increase the population of IgE+ B
lymphocytesatanyconcentrationtesteddespitethedramatic
proliferation observed for the B-lymphocyte population. In
contrast, there was a signiﬁcant increase in the number
of IgE+ B-lymphocytes in the mandibular lymph nodes at
all concentrations of OPA following OPA challenge. Nearly
50% of the B lymphocytes from mice exposed to 500ppb
OPA were positive for IgE indicating isotype switching to
an allergic phenotype, evidence that OPA may cause type I
hypersensitivity.
Isotype switching to IgE is regulated by Th2 cytokines,
namely, IL-4 [39] which is produced primarily by CD4+
Tl y m p h o c y t e s[ 40]. There was increased proliferation of
T lymphocytes following the inhalation of OPA, and these
cells likely play an important role in shaping the humoral
immune response to this chemical. The inhalation of OPA
resulted in a concentration-dependent increase in IL-4 and
IL-5 gene expression in the mandibular lymph nodes even
following sensitization exposure regimen. Mice that were
challengedwithOPAshowedsigniﬁcantupregulationofIL-4
geneexpressionatallconcentrationsofOPAsupportingclass
switching to IgE in the B-lymphocyte population. In con-
trast,Th2cytokinegeneexpressionwasunalteredinthenasal
mucosa and lung following sensitization exposure. Inhala-
tion challenge with OPA caused a marked concentration-
dependent increase in the expression of the Th2 cytokine IL-
4, IL-5, and IL-13 and to a lesser degree, the Th1 cytokine
IFNγ. This strong shift towards Th2 cytokine production
in the target mucosal tissue further supports an allergic
response to OPA inhalation. In addition to these cytokines,
the proinﬂammatory cytokine IL-1β was upregulated and is
known to play an important role in priming antigen present-
ing cells. Th2 cytokine gene expression in the lungs was also
upregulated in mice that received the challenge exposure to
OPA although not statistically signiﬁcant. The ability of OPA
to stimulate Th2 and proinﬂammatory cytokines may be
one mechanism responsible for its adjuvant-like properties
observed in a murine OVA allergy model [11].
Overall, the ﬁndings of this study demonstrate that OPA
hasthepotentialtoinducerespiratorysensitizationfollowing
inhalation exposure. Characteristics of the immune response
to OPA suggest that exposure to this chemical may cause a
type I hypersensitivity response as there was a large increase
in the IgE+ B-lymphocyte population. The immune response
to OPA is similar to other low and high molecular weight
chemicals that are known to cause occupational rhinitis and
asthma, indicating the need for the regulation of OPA in
the workplace. The concentration range tested in the present
study is at least 10 fold higher than air concentrations that
can be found in the workplace [14]. Therefore, further stud-
ies with lower concentrations and longer exposure periods
are important to better characterize the immunotoxicity
of OPA and to facilitate risk assessment. Additionally, the
understanding the interaction between skin and respiratory
exposure will be important for risk assessment for OPA. Pre-
vious work with other low molecular weight sensitizers have
shown that skin exposure can prime the immune system to
respond to future airway exposures [41–44]. There is a high
potential for skin exposure during manual reprocessing of
medicaldeviceswithOPA.Thepotentsensitizingresponseto
dermalexposure [9]maysigniﬁcantlylowerthethresholdair
concentration of OPA required to elicit an immune response
in the airways. Our laboratory is currently examining the
interaction between skin and airways in the development
of OPA-induced allergic respiratory disease using the mouse
model.
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